Press Releases Year None202320222021202020192018201720162015201420132012 May 22, 2023 Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index May 11, 2023 Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 9, 2023 Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) May 4, 2023 Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 April 26, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration April 18, 2023 Lineage to Present at 2023 AAPS National Biotechnology Conference March 30, 2023 Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium March 20, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit March 9, 2023 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 6, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D. March 2, 2023 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 February 22, 2023 Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications February 8, 2023 Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
May 11, 2023 Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 4, 2023 Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
April 26, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
March 30, 2023 Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
March 20, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
March 9, 2023 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 6, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
March 2, 2023 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
February 22, 2023 Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
February 8, 2023 Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
